| Expression pattern: |
UP |
| Associated gene: |
CARM1, HDAC3, STAT1 |
| Associated microRNA: |
miR-181a-5p |
| Biological function: |
promotes NSCLC progression by fostering an immunosuppressive tumor microenvironment, inducing exhaustion of antitumor immunity, and decreasing efficacy of anti-PD-1 therapy; mildly promotes proliferation. |
| Molecular mechanism: |
Acts as a ceRNA sponging miR-181a-5p to upregulate CARM1, thereby suppressing type 1 IFN response via HDAC3/STAT1 modulation and promoting immune evasion and anti-PD-1 resistance. |
| Biological pathway or process: |
immune regulation (inhibits); STING/IFN (inhibits); JAK/STAT (inhibits); proliferation (promotes); ceRNA regulation (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; FISH / smFISH; circRIP; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Wound Healing Assay; Transwell Assay; Annexin V/PI Flow Cytometry; In Vivo Animal Model; IHC (Immunohistochemistry); Clinical Sample Validation; Survival Analysis; Bioinformatics Analysis; Co-IP; Western Blot; Flow Cytometry（Non-apoptosis/cycle） |
| Clinical significance: |
High circHMGB2 expression indicates poor prognosis in NSCLC and is an independent prognostic factor; higher in patients with progressive disease after anti-PD-1 therapy. |
| Description: |
circHMGB2 (hsa_circ_0071452), derived from HMGB2, is upregulated in NSCLC (including LUAD and LUSC) and predicts poor prognosis. It acts as a ceRNA to sponge miR-181a-5p, increasing CARM1 to suppress the type 1 IFN/JAK-STAT response and promote an immunosuppressive microenvironment, thereby reducing anti-PD-1 therapeutic efficacy. |
| Confidence score: |
0.8879 |